# VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients

> **NCT03671850** · PHASE2 · UNKNOWN · sponsor: **ViGenCell Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** VT-EBV-N
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03671850
- **Lead sponsor:** ViGenCell Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-09
- **Primary completion:** 2023-12-04
- **Final completion:** 2024-06-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671850, "VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03671850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*